LabyRx Immuno-Oncology is a bio-medical company focused on developing a comprehensive platform for treating adenocarcinomas, a class of glandular-related tumors that represent approximately 40% of worldwide cancer cases and 50% of treatment-related spending. Based upon our scientists’ discovery and ongoing research into the unique adenocarcinoma target – Labyrinthin – the Company aims to advance novel cancer therapeutic technologies that improve treatment processes. The team comprise renown scientists in the United States and Hong Kong working towards cancer therapeutics and diagnostics.
